Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) saw a large decrease in short interest in August. As of August 31st, there was short interest totalling 3,770,000 shares, a decrease of 16.6% from the August 15th total of 4,520,000 shares. Based on an average trading volume of 1,200,000 shares, the short-interest ratio is presently 3.1 days.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the stock. Canaccord Genuity Group upped their target price on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Raymond James increased their price objective on Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. The Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the company from $198.00 to $370.00 in a report on Friday, August 16th. Barclays upped their price target on Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, August 30th. Seven equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $279.14.
View Our Latest Stock Analysis on Alnylam Pharmaceuticals
Insider Activity at Alnylam Pharmaceuticals
Institutional Trading of Alnylam Pharmaceuticals
Large investors have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company’s stock worth $1,792,542,000 after acquiring an additional 50,366 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Alnylam Pharmaceuticals by 5.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock worth $550,837,000 after purchasing an additional 201,784 shares in the last quarter. Capital International Investors raised its stake in Alnylam Pharmaceuticals by 1.8% in the 1st quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock valued at $545,674,000 after purchasing an additional 64,560 shares during the last quarter. Capital Research Global Investors raised its stake in Alnylam Pharmaceuticals by 7.3% in the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after purchasing an additional 214,908 shares during the last quarter. Finally, Norges Bank purchased a new position in Alnylam Pharmaceuticals in the 4th quarter valued at about $390,438,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.
Alnylam Pharmaceuticals Stock Up 1.4 %
Shares of NASDAQ:ALNY opened at $265.27 on Monday. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $287.55. The company has a 50-day moving average price of $258.53 and a 200 day moving average price of $195.09. The company has a market cap of $34.06 billion, a P/E ratio of -98.98 and a beta of 0.38.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. The business’s revenue for the quarter was up 107.0% compared to the same quarter last year. During the same period last year, the company earned ($2.21) earnings per share. Analysts expect that Alnylam Pharmaceuticals will post -2.73 EPS for the current year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Featured Articles
- Five stocks we like better than Alnylam Pharmaceuticals
- Why Are Stock Sectors Important to Successful Investing?
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- Profitably Trade Stocks at 52-Week Highs
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- Best Stocks Under $10.00
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.